The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis

Clinical Immunology and Immunopathology

Volumn 87, Issue 3, 1998, Pages 266-275

  Dedhia, Vinesh ^a   Goluszko, Elzbieta ^a   Wu, Bo ^a   Deng, Caishu ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antigen presentation; B cells; Immune response; Myasthenia gravis; gene knockout

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY;

ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNE RESPONSE; LYMPHOCYTE FUNCTION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0031783091     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1998.4535     Document Type: Article

References (44)

1. Richman D. P., Antel J. P., Patrick J. W., Arnason B. G. Cellular immunity to acetylcholine receptor in myasthenia gravis. Relationship to histocompatibility type and antigenic site. Neurology. 29:1979;291-296.
2. Conti-Tronconi B. M., Morgutti M., Sghirlanzoni A., Clementi F. Cellular immune response against acetylcholine receptor in myasthenia gravis. I. Relevance to clinical course and pathogenesis. Neurology. 29:1979;496-501.
3. Kaul R., Shenoy M., Goluszko E., Christadoss P. MHC class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:1994;3152-3157.
4. Christadoss P., Dauphinee M. Immunotherapy for myasthenia gravis. J. Immunol. 136:1986;2437-2440.
5. Waldor M., Sriram S., McDevitt H., Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. Proc. Natl. Acad. Sci. USA. 80:1983;2713-2717.
6. Fambrough D. M., Drachman D. B., Satyamurti S. Neuromuscular junction in myasthenia gravis. Decreased acetylcholine receptors. Science. 182:1973;293-295.
7. Lindstrom J., Shelton D., Fujii Y. Myasthenia gravis. Adv. Immunol. 42:1988;233-284.
8. Drachman D. B. Myasthenia gravis. N. Eng. J. Med. 330:1994;1797-1810.
9. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9:1989;247-278.
10. Christadoss P., Shenoy M. Molecular immunopathogenesis of experimental autoimmune myasthenia gravis. Regional Immunol. 4:1993;314-320.
11. Wu, B. Goluszko, E. Christadoss, P. Experimental autoimmune myasthenia gravis in mice, In, Protocols in Immunology, 3, 15.8.1, Wiley, New York.
12. Janeway C. A., Ron J., Katz M. E. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J. Immunol. 138:1987;1051-1055.
13. Liu Y., Wu Y., Ramarathinam L., Guo Y., Huszar D., Trounstine M., Zhao M. Gene-targeted B deficient mice reveal a critical role for B cells in the CD4 cell response. Int. Immunol. 7:1995;1353-1362.
14. Epstein M. M., DiRosa F., Jankovic D., Sher A., Matzinger P. Successful T cell priming in B cell deficient mice. J. Exp. Med. 182:1995;915-922.
15. +. J. Exp. Med. 183:1996;1339-1344.
16. Chowdhury M. G. M., Maeda K., Yasutomo K., Maekawa Y., Furukawa A., Azuma M., Nagasawa H., Himeno K. Antigen-specific B cells are required for the secondary response of T cells but not for their priming. Eur. J. Immunol. 26:1996;1628-1633.
17. Robinson T. A. W., Phillips R. S. Reconstitution of B cell depleted mice with B cells restores Th2 type immune response duringPlasmodium chabaudi chabaudi. Infect. Immunol. 64:1996;366-370.
18. +Plasmodium chabaudi chabaudi. Int. Immunol. 5:1993;1343-1348.
19. Wolf S. D., Dittel B. N., Hardardottir F., Janeway C. A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J. Exp. Med. 184:1996;2271-2278.
20. +. J. Immunol. 154:1995;4915-4923.
21. +. J. Immunol. 155:1995;1353-1362.
22. Kitamura D., Roes J., Kühn R., Rajewsky K. B cell deficient mouse by targeted disruption of the membrane exon of the immunglobulin μ chain gene. Nature. 350:1991;423-426.
23. Sahashi K., Engel A., Lambert E., Howard F. Ultrastructural localization of the terminal and lytic ninth complement (C9) at the motor endplate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39:1980;160-172.
24. Buzzard E. F. The clinical history and post-mortem examination of five cases of myasthenia gravis. Brain. 28:1905;438.
25. Pascuzzi R. M., Campa J. F. Lymphorrhage localized to the muscle endplate in myasthenia gravis. Arch. Pathol. Lab. Med. 112:1988;934-937.
26. Lefvert A. K., Bergstrom K., Matell G., Osterman P. O., Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenic implications. J. Neurol. Neurosurg. Psychiatry. 41:1978;394-403.
27. Soliven B. C., Lange D. J., Penn A. S., Younger D., Jaretzki A., Lovelace R. E., Rowland L. P. Seronegative myasthenina gravis. Neurology. 38:1988;514-517.
28. Mossman S., Vincent A., Newsom-Davis J. Myasthenia gravis without acetylcholine receptor antibody: A distinct disease entity. Lancet. i:1986;116-119.
29. Gu D., Wogensen L., Calcutt N., Xia C., Zhu S., Merlie J., Fox H., Lindstrom J., Powell H., Sarvetnick N. Myasthenia gravis-like syndrome induced by expression of γ-IFN in the neuromuscular junction. J. Exp. Med. 181:1995;547-557.
30. +. Eur. J. Immunol. 25:1995;1191-1198.
31. +. Scand. J. Immunol. 42:1995;457-465.
32. ++. J. Exp. Med. 184:1996;349-356.
33. Lindstrom J., Einarson B., Tzartos S. Production and assay of antibodies to acetylcholine receptor. Methods Enzymol. 74:1981;432-460.
34. Shenoy M., Oshima M., Atassi M. Z., Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:1993;230-238.
35. Deng C., Goluszko E., Baron S., Wu B., Christadoss P. Interferon α therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:1996;5675.
36. Ron Y., Sprent J. T cell priming in vivo: A major role for B cells in presenting antigen to T cells in lymph nodes. J .Immunol. 138:1987;2848-2856.
37. Kurt-Jones E. A., Liano D., HayGlass K. A., Benaceraff B., Sy M. S., Abbas A. K. The role of antigen presenting B cells in T cell priming in vivo. J. Immunol. 140:1988;3773-3778.
38. Mamula M. J., Janeway C. A. Jr. Do B cells drive the diversification of immune response. Immunol. Today. 14:1993;151-152.
39. Richman D. P., Wollman R. L., Maselli R. A., Gomez C. M., Corey A. L., Agius M. A., Fairclough R. H. Effector mechanisms of myasthenic antibodies. Myasthenia gravis and related disorders. Ann. N.Y. Acad. Sci. 681:1993;264-273.
40. Corey A. L., Richman D. P., Schuman C. A., Gomez C. M., Arnason B. G. W. Use of monoclonal anti-acetylcholine receptor antibodies to investigate the macrophage inflammation of acute experimental myasthenia gravis: Refractoriness to second episode of acute disease. Neurology. 35:1985;1455-1460.
41. Corey A. L., Richman D. P., Wollman R. L., Agius M. A. Refractoriness to second episode of experimental myasthenia gravis: Correlation with acetylcholine receptor concentration and morphologic appearance of post-synaptic membrane. J. Immunol. 138:1987;3269-3275.
42. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140:1988;2589-2592.
43. Durie F., Fava R., Foy T., Aruffo A., Ledbetter J., Noelle R. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science. 261:1993;1328-1330.
44. Mohan C., Shi Y., Laman J., Datta S. Interaction between CD40 and its ligand in the development of murine lupus nephritis. J. Immunol. 154:1994;1470-1480.